arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ACADIA PHARMACEUTICALS INC

ACAD
$21.23 ▼ -0.26 (-1.21%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

ACADIA PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $3.6B
Dividend Yield —
Revenue Growth 11.9% ↘
Op. Margin 9.8% ↘
ROIC 24.0% ↘
FCF / Share $0.62 ↘
Trailing P/E 9.2x
Price / Book 3.0x
FCF Yield 2.9%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.07B
↑ +11.9% —
Net Income Profit after all expenses
$391.00M
↑ +72.7% —
Operating Margin Operating profit as % of sales
9.8%
↓ -59.4% 56th
FCF / Share Free cash flow per share
$0.62
↓ -34.2% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
71
Returns
93
Cash Quality ↓
31

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters